

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

Use this form for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/821,718

Filing Date

April 9, 2004

First Named Inventor

Clyde Schultz

Art Unit

1615

Examiner Name

Attorney Docket Number

RH01.701US

ENCLOSURES (Check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/
Incomplete Application
<input type="checkbox"/> Reply to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> Other Enclosure(s) (please identify
below): |
|---|--|---|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Finch IP PLLC

Signature

Printed name

Stephen Finch

Date

December 19, 2005

Reg. No.

42,534

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Mary Boyd

Date

December 19, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



S/N 10/821,718

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Clyde Schultz	Examiner:	Unknown
Serial No.:	10/821,718	Group Art Unit:	1615
Filed:	April 9, 2004	Docket:	RH01.701US
Title:	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503421 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

INFORMATION DISCLOSURE STATEMENT

Page 2

Serial No :10/821,718

Dkt: RH01.701US

Filing Date: April 9, 2004

Title: Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

Respectfully submitted,

CLYDE SCHULTZ


By his Representatives,

Finch IP PLLC


P.O. Box 1358, Concord, NH 03302

Date December 19, 2005

By


Stephen Finch
Reg. No. 42,534

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 19th day of December, 2005.


Mary Boyd

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/821,718
Filing Date	April 9, 2004
First Named Inventor	Schultz, Clyde
Group Art Unit	1615
Examiner Name	Unknown

Attorney Docket No: RH01.701US

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-20050255144	11/17/2005	Schultz	
	US-20050074497	04/07/2005	Schultz	
	US-4753945	06/28/1988	Gilbard et al.	
	US-5723131	03/03/1998	Schultz et al.	
	US-6051698	04/18/2000	Janjic et al.	
	US-6277855	08/21/2001	Yerxa	
	US-6566398	05/20/2003	Ueno	
	US-6645978	11/11/2003	Gamache et al.	
	US-6645994	11/11/2003	Gamache	
	US-6659985	12/09/2003	Connor	
	US-6,825,232	11/30/2004	Gamache	
	US-6,426,335	07/30/2002	Janjic, et al.	
	US-20030069560	04/10/2003	Adamis, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO03/092665 A2	11/13/2003	Massachusetts Eye and Ear Infirmary	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHMIDT, "Back of the Eye: The Fifth Wave in Ophthalmology", <u>Medical Supplies & Devices</u> , 40 pages, SG Cowen dated December 2003	
		SCHULTZ, "Drug and Growth Factor Delivery for the Treatment of Ocular Syndromes from Hydrogel Materials", Presented by the American Society for Microbiology Meeting in Washington DC in May of 2003, Session #181, Poster #O-081,	
		WIJNGAARDEN, "Inhibitors of Ocular Neovascularization", <u>American Medical Association</u> , Vol. 293, No. 12, (03/23/2005), 1509-1512	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached